• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

第六和第七版晚期乳腺癌国际共识诊治指南（ABC 指南 6 和 7）。

6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).

机构信息

Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, and ABC Global Alliance, Lisbon, Portugal.

Hadassah University Hospital - Sharett Institute of Oncology, Jerusalem, Israel.

出版信息

Breast. 2024 Aug;76:103756. doi: 10.1016/j.breast.2024.103756. Epub 2024 May 28.

DOI:10.1016/j.breast.2024.103756
PMID:38896983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11231614/
Abstract

This manuscript describes the Advanced Breast Cancer (ABC) international consensus guidelines updated at the last two ABC international consensus conferences (ABC 6 in 2021, virtual, and ABC 7 in 2023, in Lisbon, Portugal), organized by the ABC Global Alliance. It provides the main recommendations on how to best manage patients with advanced breast cancer (inoperable locally advanced or metastatic), of all breast cancer subtypes, as well as palliative and supportive care. These guidelines are based on available evidence or on expert opinion when a higher level of evidence is lacking. Each guideline is accompanied by the level of evidence (LoE), grade of recommendation (GoR) and percentage of consensus reached at the consensus conferences. Updated diagnostic and treatment algorithms are also provided. The guidelines represent the best management options for patients living with ABC globally, assuming accessibility to all available therapies. Their adaptation (i.e. resource-stratified guidelines) is often needed in settings where access to care is limited.

摘要

本手稿描述了在最近两次 ABC 国际共识会议（2021 年的 ABC6，虚拟会议，和 2023 年在葡萄牙里斯本举行的 ABC7）上更新的高级乳腺癌（ABC）国际共识指南，由 ABC 全球联盟组织。它提供了关于如何最好地管理所有乳腺癌亚型的局部晚期或转移性不可手术的晚期乳腺癌患者的主要建议，以及姑息和支持性护理。这些指南基于现有证据或缺乏更高证据水平时的专家意见。每条指南都附有证据水平（LoE）、推荐等级（GoR）和共识会议达成的共识百分比。还提供了更新的诊断和治疗算法。这些指南代表了全球范围内 ABC 患者的最佳管理选择，假设可以获得所有可用的治疗方法。在获得治疗的机会有限的情况下，通常需要对这些指南进行调整（即资源分层指南）。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/80cfcd07ce7f/gr6b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/3de1e4f39d63/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/677a0e2ac742/fx2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/61e414eed29e/fx3a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/50bd1705dc89/fx3b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/06f72afeffd7/fx3c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/a3d908cc020a/fx3d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/40b4bfb98bdd/fx3e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/4687849a5558/fx3f.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/51243648dc6f/fx4a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/288e23791a45/fx4b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/f08291adfb73/fx4c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/e5bd2e45ec32/fx4d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/476c64fcdfb9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/20501f7b4aa8/fx5a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/52c314fc38b2/fx5b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/16158e05e5e4/fx5c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/77ce7dad908b/fx5e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/d3f23f1f8b74/fx5f.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/3ca4412ab9a1/fx5g.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/88bdde96cccc/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/f8de7845b884/fx6a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/37a3e634b30a/fx6b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/e1761837f2dd/fx6c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/3facc611b87b/fx6d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/c6b61e8c9e40/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/f75643514723/fx7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/494647819acf/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/60ebc0c45699/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/721d7b95e191/fx8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/f88161b43b21/fx9a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/cdfa696a114b/fx9b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/08553ca9a9e0/fx10a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/e394c57e0442/fx10b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/8e81e7188482/fx10c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/cc97b32fd828/fx10d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/19d9ca2442dc/fx11a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/bbfee1e6d815/fx11b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/9f577d1ef006/fx11c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/59c12a78e16d/fx11d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/86507e9c053d/fx11e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/9ef1017eb39d/fx12a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/88276a585686/fx12c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/e99caf51c398/fx12d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/ae3443725cc5/fx12e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/a6a66ee0f56c/fx13a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/dbf6c68ae457/fx13b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/74555d867009/fx13d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/862573c7476a/fx13f.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/80cfcd07ce7f/gr6b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/3de1e4f39d63/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/677a0e2ac742/fx2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/61e414eed29e/fx3a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/50bd1705dc89/fx3b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/06f72afeffd7/fx3c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/a3d908cc020a/fx3d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/40b4bfb98bdd/fx3e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/4687849a5558/fx3f.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/51243648dc6f/fx4a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/288e23791a45/fx4b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/f08291adfb73/fx4c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/e5bd2e45ec32/fx4d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/476c64fcdfb9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/20501f7b4aa8/fx5a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/52c314fc38b2/fx5b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/16158e05e5e4/fx5c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/77ce7dad908b/fx5e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/d3f23f1f8b74/fx5f.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/3ca4412ab9a1/fx5g.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/88bdde96cccc/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/f8de7845b884/fx6a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/37a3e634b30a/fx6b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/e1761837f2dd/fx6c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/3facc611b87b/fx6d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/c6b61e8c9e40/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/f75643514723/fx7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/494647819acf/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/60ebc0c45699/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/721d7b95e191/fx8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/f88161b43b21/fx9a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/cdfa696a114b/fx9b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/08553ca9a9e0/fx10a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/e394c57e0442/fx10b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/8e81e7188482/fx10c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/cc97b32fd828/fx10d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/19d9ca2442dc/fx11a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/bbfee1e6d815/fx11b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/9f577d1ef006/fx11c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/59c12a78e16d/fx11d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/86507e9c053d/fx11e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/9ef1017eb39d/fx12a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/88276a585686/fx12c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/e99caf51c398/fx12d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/ae3443725cc5/fx12e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/a6a66ee0f56c/fx13a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/dbf6c68ae457/fx13b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/74555d867009/fx13d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/862573c7476a/fx13f.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b181/11231614/80cfcd07ce7f/gr6b.jpg

相似文献

1
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).第六和第七版晚期乳腺癌国际共识诊治指南（ABC 指南 6 和 7）。
Breast. 2024 Aug;76:103756. doi: 10.1016/j.breast.2024.103756. Epub 2024 May 28.
2
1st International consensus guidelines for advanced breast cancer (ABC 1).1 期国际乳腺癌治疗共识指南（ABC1）。
Breast. 2012 Jun;21(3):242-52. doi: 10.1016/j.breast.2012.03.003. Epub 2012 Mar 16.
3
Challenges in optimizing care in advanced breast cancer patients: Results of an international survey linked to the ABC1 consensus conference.晚期乳腺癌患者优化治疗的挑战：一项与ABC1共识会议相关的国际调查结果
Breast. 2015 Oct;24(5):623-9. doi: 10.1016/j.breast.2015.06.008. Epub 2015 Jul 19.
4
Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective.第二届高级乳腺癌国际共识会议（ABC2），2013 年 9 月 11 日，里斯本：德国视角。
Breast Care (Basel). 2014 Feb;9(1):52-9. doi: 10.1159/000358689.
5
Supportive and palliative care for metastatic breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement.转移性乳腺癌的支持性和姑息治疗：中低收入国家的资源配置。2013 年乳腺健康全球倡议共识声明。
Breast. 2013 Oct;22(5):616-27. doi: 10.1016/j.breast.2013.07.052. Epub 2013 Aug 21.
6
4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts.第四届晚期乳腺癌国际共识会议（ABC4），里斯本，2017年11月4日：ABC4共识：德国专家小组评估
Geburtshilfe Frauenheilkd. 2018 May;78(5):469-480. doi: 10.1055/a-0594-2243. Epub 2018 Jun 4.
7
ABC7 Consensus: Assessment by a German Group of Experts.ABC7共识：德国专家小组的评估
Breast Care (Basel). 2024 Apr;19(2):116-128. doi: 10.1159/000535997. Epub 2024 Jan 24.
8
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).第三届欧洲中学教育阶段（ESO）-欧洲肿瘤内科学会（ESMO）晚期乳腺癌国际共识指南（ABC 3）
Breast. 2017 Feb;31:244-259. doi: 10.1016/j.breast.2016.10.001. Epub 2016 Dec 5.
9
Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines.资源有限国家的乳腺癌：《2005年全球乳腺癌防治倡议》指南概述
Breast J. 2006 Jan-Feb;12 Suppl 1:S3-15. doi: 10.1111/j.1075-122X.2006.00199.x.
10
Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.专家共识：晚期或转移性上皮性卵巢癌的评估和管理。
Rev Colomb Obstet Ginecol. 2024 Jun 14;75(1):4094. doi: 10.18597/rcog.4094.

引用本文的文献

1
The association between young age at metastatic breast cancer diagnosis and overall survival in the EMBRACE study.EMBRACE研究中转移性乳腺癌诊断时的年轻年龄与总生存期之间的关联。
NPJ Breast Cancer. 2025 Aug 29;11(1):96. doi: 10.1038/s41523-025-00822-y.
2
Transcriptomic and microenvironment characteristics of triple-negative breast cancer under three different neoadjuvant treatment regimens.三种不同新辅助治疗方案下三阴性乳腺癌的转录组学和微环境特征
Breast Cancer Res Treat. 2025 Aug 27. doi: 10.1007/s10549-025-07810-7.
3
Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.
一线与二线CDK4/6抑制在激素受体阳性、HER2阴性转移性乳腺癌中的疗效比较
Breast Cancer Res. 2025 Aug 13;27(1):146. doi: 10.1186/s13058-025-02095-6.
4
[Not Available].[无可用内容]
Wien Klin Wochenschr. 2025 Jul 31. doi: 10.1007/s00508-025-02582-y.
5
PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ERHER2 breast cancer harbouring acquired ESR1 mutations.PROTAC SERD药物维迪西妥昔单抗在携带获得性ESR1突变的晚期ER⁺HER2⁻乳腺癌中表现优于氟维司群。
Nat Rev Clin Oncol. 2025 Jul 22. doi: 10.1038/s41571-025-01062-6.
6
F-fluoroestradiol (F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival.F-氟雌二醇（F-FES）PET/CT用于指导HR + /HER2-转移性乳腺癌患者的一线治疗：对无进展生存期的影响
Eur J Nucl Med Mol Imaging. 2025 Jul 19. doi: 10.1007/s00259-025-07459-w.
7
A direct comparison of classical oral Navelbine vs metronomic Navelbine in metastatic breast cancer: results from the Danish Breast Cancer Group's (DBCG) NAME-trial.转移性乳腺癌中传统口服长春瑞滨与节拍性长春瑞滨的直接比较：丹麦乳腺癌协作组（DBCG）NAME试验的结果
Breast Cancer Res Treat. 2025 Sep;213(2):237-246. doi: 10.1007/s10549-025-07777-5. Epub 2025 Jul 11.
8
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.GEICAM/2013 - 02 PEARL试验中，帕博西尼+内分泌治疗与卡培他滨治疗芳香化酶抑制剂耐药乳腺癌的生存转录组预测指标
JCO Precis Oncol. 2025 Jul;9:e2400937. doi: 10.1200/PO-24-00937. Epub 2025 Jul 9.
9
Underserved Patient Populations With Metastatic Breast Cancer: A Review of Progress and Remaining Challenges.转移性乳腺癌患者的医疗服务不足群体：进展与尚存挑战综述
Breast J. 2025 Jun 30;2025:2461234. doi: 10.1155/tbj/2461234. eCollection 2025.
10
Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial.HER2阴性晚期乳腺癌患者中预防赛托珠单抗戈维汀相关中性粒细胞减少和腹泻的研究（PRIMED）：一项开放标签、单臂、2期试验
EClinicalMedicine. 2025 Jun 18;85:103309. doi: 10.1016/j.eclinm.2025.103309. eCollection 2025 Jul.